Olga S Kolovskaya Selected Research

Nucleotide Aptamers

12/2021	11C-radiolabeled aptamer for imaging of tumors and metastases using positron emission tomography- computed tomography.
1/2020	Aptamer-Conjugated Superparamagnetic Ferroarabinogalactan Nanoparticles for Targeted Magnetodynamic Therapy of Cancer.
3/2019	Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood.
3/2017	DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma.
1/2017	Noninvasive Microsurgery Using Aptamer-Functionalized Magnetic Microdisks for Tumor Cell Eradication.
1/2017	In Vivo Cancer Cells Elimination Guided by Aptamer-Functionalized Gold-Coated Magnetic Nanoparticles and Controlled with Low Frequency Alternating Magnetic Field.
10/2016	Electrochemical aptasensor for lung cancer-related protein detection in crude blood plasma samples.
9/2015	Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood.
4/2014	DNA-aptamer targeting vimentin for tumor therapy in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Olga S Kolovskaya Research Topics

Disease

12	Neoplasms (Cancer) 12/2021 - 04/2014
6	Lung Neoplasms (Lung Cancer) 09/2021 - 09/2015
3	Carcinoma (Carcinomatosis) 01/2020 - 01/2017
2	Circulating Neoplastic Cells 03/2019 - 09/2015
2	Neoplasm Metastasis (Metastasis) 11/2017 - 09/2015
2	Adenocarcinoma of Lung 03/2017 - 09/2015
1	Epilepsy (Aura) 03/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2019
1	Ascites 04/2014
1	Adenocarcinoma 04/2014

Drug/Important Bio-Agent (IBA)

9	Nucleotide AptamersIBA 12/2021 - 04/2014
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2015
3	AntibodiesIBA 03/2019 - 03/2017
3	GoldIBA 12/2017 - 10/2016
3	Biomarkers (Surrogate Marker)IBA 11/2017 - 09/2015
2	Pharmaceutical PreparationsIBA 12/2021 - 01/2017
2	arabinogalactanIBA 01/2020 - 04/2014
2	OligonucleotidesIBA 01/2020 - 11/2017
2	Fibronectins (Fibronectin)IBA 01/2020 - 01/2017
2	VimentinIBA 09/2015 - 04/2014
1	DNA PrimersIBA 12/2021
1	A-Form DNA (A-DNA)IBA 09/2021
1	LigandsIBA 05/2021
1	Syntex adjuvant formulationIBA 05/2021
1	Nucleic AcidsIBA 03/2020
1	Asialoglycoprotein ReceptorIBA 01/2020
1	Epithelial Cell Adhesion MoleculeIBA 03/2019
1	Glucose (Dextrose)FDA LinkGeneric 12/2017
1	Biological ProductsIBA 11/2017
1	Monoclonal AntibodiesIBA 03/2017
1	Contrast MediaIBA 01/2017
1	IntegrinsIBA 01/2017
1	hexacyanoferrate III (ferricyanide)IBA 10/2016
1	SolutionsIBA 10/2016
1	StreptavidinIBA 10/2016
1	hexacyanoferrate II (ferrocyanide)IBA 10/2016
1	Histones (Histone)IBA 09/2015
1	DefensinsIBA 09/2015
1	Annexin A5IBA 09/2015
1	Annexin A2 (Annexin II)IBA 09/2015
1	ClusterinIBA 09/2015

Therapy/Procedure

10	Therapeutics 12/2021 - 04/2014
2	Precision Medicine 05/2021 - 01/2020
1	Lasers (Laser) 12/2017
1	Injections 12/2017
1	Photothermal Therapy 12/2017
1	Microelectrodes 10/2016